Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
|Articles|March 4, 2011
Oncology Nursing News
- February 2011
- Volume 5
- Issue 1
Behavioral Therapy Alleviates Prostatectomy-Induced Incontinence
Author(s)Onclive Team
Behavioral therapy reduced episodes of urinary incontinence following radical prostatectomy by 55% in a study of 208 men with incontinence persisting %u22651 year following prostatectomy.
Advertisement
Journal of the American Medical Association
Behavioral therapy reduced episodes of urinary incontinence following radical prostatectomy by 55% in a study of 208 men with incontinence persisting ≥1 year following prostatectomy. The 8-week behavioral training program included pelvic fl oor muscle exercises, self-monitoring with bladder diaries, regular office visits, bladder control techniques, and fl uid management. Over the same period, incontinence-episodes fell only 24% in the control group. The study was published in the .
Articles in this issue
over 15 years ago
Exercise, Weight-Lifting Help in Preventing Lymphedemaover 15 years ago
Sexual Health & Cancerover 15 years ago
The Emperor of All Maladies: Documenting Cancer's Long Reignover 15 years ago
Do Breast Implants Increase Cancer Risk?over 15 years ago
National Patient Safety Goals: 2011 Updatesover 15 years ago
I'm Too Young for This!over 15 years ago
Avastin Alarmover 15 years ago
Low-Dose Aspirin Cuts Cancer Death RateAdvertisement
Related to this article
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The enzalutamide bioequivalent received tentative FDA approval, pending patent expiry on branded Xtandi before final marketing authorization.
Vernon Sondak, MD, discusses CSCC risk classification, adjuvant cemiplimab in extremely high-risk disease, and the promise of neoadjuvant immunotherapy.
Hagop Kantarjian, MD, discusses the arsenal of TKIs approved for chronic myeloid leukemia and how to navigate them regarding treatment selection.
Priya Rastogi, MD, discusses findings from a sub-study of the GeparDouze trial evaluating the effects of ctDNA positivity on treatment outcomes in TNBC.
Advertisement
Advertisement
Trending on OncLive
1
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
2
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
3
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
4
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
5